HHS Seeks Early Win Defending Medicare Drug Price Program

By Dan McKay · December 21, 2023, 7:24 PM EST

Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Dan

July 23, 2024
Dead Or Not Quite: Hospitals Weigh Shared Definition Of DOA
July 23, 2024
Hospital Cites Rare Doctrine In Colo. Trans Care Clash
July 16, 2024
Ex-FDA Head Calls For Congressional Action On Medical AI
July 16, 2024
In Chevron's Fall, Attys See Conflicting Rulings, Circuit Splits
July 09, 2024
Calif. Health Players Back Managed Care Tax Amid Uncertainty
July 02, 2024
Arizona AG Abortion Opinion May Influence Courts, Doctors
July 02, 2024
Whistleblower Or Felon? Texas Doc Faces Rare HIPAA Charge
June 28, 2024
Iowa Supreme Court Approves 6-Week Abortion Ban
June 25, 2024
Supreme Court Sets Stage For Crucial Ruling On Trans Rights
June 24, 2024
High Court To Review State Gender Care Bans